We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Beetstra, S, Suthers, G, Dhillon, V, Salisbury, C, Turner, J, Altree, M, McKinnon, R, Fenech, M. Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. Cancer Epidemiol Biomarkers Prev2008; 17: 2565–2571.CrossRefGoogle Scholar
2
2.Bempt, IV, Van Loo, P, Drijkoningen, M, Neven, P, Smeets, A, Christiaens, MR, Paridaens, R, De Wolf-Peeters, C. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol2008; 26: 4869–4874.CrossRefGoogle Scholar
4.Castro-Rivera, E, Ran, S, Brekken, RA, Minna, JD. Semaphorin 3B inhibits the Phosphatidylinositol 3-Kinase/Akt Pathway through Neuropilin-1 in lung and breast cancer cells. Cancer Res2008; 68: 8295–8303.CrossRefGoogle ScholarPubMed
5
5.Conzen, SD. Nuclear receptors and breast cancer. Mol Endocrinol2008; 22: 2215–2228.CrossRefGoogle ScholarPubMed
6
6.Davis, VL, Jayo, MJ, Ho, A, Kotlarczyk, MP, Hardy, ML, Foster, WG, Hughes, CL. Black Cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res2008; 68: 8377–8383.CrossRefGoogle ScholarPubMed
7
7.DuSell, CD, McDonnell, DP. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends Pharmacol Sci2008; 29: 510–514.CrossRefGoogle ScholarPubMed
8
8.Eisen, A, Lubinski, J, Gronwald, J, Moller, P, Lynch, HT, Klijn, J, Kim-Sing, C, Neuhausen, SL, Gilbert, L, Ghadirian, P, Manoukian, S, Rennert, G, Friedman, E, Isaacs, C, Rosen, E, Rosen, B, Daly, M, Sun, P, Narod, SAHormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst2008; 100: 1361–1367.CrossRefGoogle ScholarPubMed
9
9.Ellis, MJ, Tao, Y, Luo, JQ, A’Hern, R, Evans, DB, Bhatnagar, AS, Ross, HAC, von Kameke, A, Miller, WR, Smith, I, Eiermann, W, Dowsett, M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst2008; 100: 1380–1388.CrossRefGoogle ScholarPubMed
10
10.Fabre, A, Fournier, A, Mesrine, S, Gompel, A, Desreux, J, Berrino, F, Boutron-Ruault, MC, Romieu, I, Clavel-Chapelon, F. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. Cancer Epidemiol Biomarkers Prev2008; 17: 2723–2728.CrossRefGoogle ScholarPubMed
11
11.Firlej, V, Ladam, F, Brysbaert, G, Dumont, P, Fuks, F, de Launoit, Y, Benecke, A, Chotteau-Lelievre, A. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. J Cell Sci2008; 121: 3393–3402.CrossRefGoogle ScholarPubMed
12
12.Gaudet, MM, Chanock, S, Dunning, A, Driver, K, Brinton, LA, Lissowska, J, Peplonska, B, Pharoah, P, Garcia-Closas, M. HSD17B1 genetic variants and hormone receptor-defined breast cancer. Cancer Epidemiol Biomarkers Prev2008; 17: 2766–2772.CrossRefGoogle ScholarPubMed
13
13.Ginsburg, OM, Martin, LJ, Boyd, NF. Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer2008; 99: 1369–1374.CrossRefGoogle ScholarPubMed
14
14.Green, CA, Peter, MB, Speirs, V, Shaaban, AM. The potential role of ER β isoforms in the clinical management of breast cancer. Histopathology2008; 53: 374–380.CrossRefGoogle ScholarPubMed
15
15.Guerra, E, Trerotola, M, Dell’Arciprete, R, Bonasera, V, Palombo, B, El-Sewedy, T, Ciccimarra, T, Crescenzi, C, Lorenzini, F, Rossi, C, Vacca, G, Lattanzio, R, Piantelli, M, Alberti, S. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res2008; 68: 8113–8121.CrossRefGoogle ScholarPubMed
16
16.Haibe-Kains, B, Desmedt, C, Sotiriou, C, Bontempi, G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?Bioinformatics2008; 24: 2200–2208.CrossRefGoogle Scholar
17
17.Howe, LR, Lippman, SM. Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst2008; 100: 1420–1423.CrossRefGoogle ScholarPubMed
18
18.Hwang, KT, Han, W, Cho, J, Lee, JW, Ko, E, Kim, EK, Jung, SY, Jeong, EM, Bae, JY, Kang, JJ, Yang, SJ, Kim, SW, Noh, DY. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer2008; 123: 1807–1815.CrossRefGoogle ScholarPubMed
19
19.John, S, Nayvelt, I, Hsu, HC, Yang, PA, Liu, WS, Das, GM, Thomas, T, Thomas, TJ. Regulation of estrogenic effects by Beclin 1 in breast cancer cells. Cancer Res2008; 68: 7855–7863.CrossRefGoogle ScholarPubMed
20
20.Kabil, A, Silva, E, Kortenkamp, A. Estrogens and genomic instability in human breast cancer cells – involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals. Carcinogenesis2008; 29: 1862–1868.CrossRefGoogle ScholarPubMed
21
21.Katsuno, Y, Hanyu, A, Kanda, H, Ishikawa, Y, Akiyama, F, Iwase, T, Ogata, E, Ehata, S, Miyazono, K, Imamura, T,. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene2008; 27: 6322–6333.CrossRefGoogle ScholarPubMed
22
22.Kavanagh, AM, Byrnes, GB, Nickson, C, Cawson, JN, Giles, GG, Hopper, JL, Gertig, DM, English, DR. Using mammographic density to improve breast cancer screening outcomes. Cancer Epidemiol Biomarkers Prev2008; 17: 2818–2824.CrossRefGoogle ScholarPubMed
23
23.Leary, RJ, Lin, JC, Cummins, J, Boca, S, Wood, LD, Parsons, DW, Jones, S, Sjoblom, T, Park, BH, Parsons, R, Willis, J, Dawson, D, Willson, JKV, Nikolskaya, T, Nikolsky, Y, Kopelovich, L, Papadopoulos, N, Pennacchio, LA, Wang, TL, Markowitz, SD, Parmigiani, G, Kinzler, KW, Vogelstein, B, Velculescu, VE. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA2008; 105: 16224–16229.CrossRefGoogle ScholarPubMed
24
24.Liapis, E, McLuckie, KIE, Lewis, PD, Farmer, PB, Brown, K. Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots. Nucleic Acids Res2008; 36: 5933–5945.CrossRefGoogle ScholarPubMed
25
25.Linos, E, Spanos, D, Rosner, BA, Linos, K, Hesketh, T, Qu, JD, Gao, YT, Zheng, W, Colditz, GA. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst2008; 100: 1352–1360.CrossRefGoogle Scholar
26
26.Marlow, R, Strickland, P, Lee, JS, Wu, XY, PeBenito, M, Binnewies, M, Le, EK, Moran, A, Macias, H, Cardiff, RD, Sukumar, S, Hinck, L. SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res2008; 68: 7819–7827.CrossRefGoogle ScholarPubMed
27
27.Mazan-Mamczarz, K, Hagner, PR, Dai, BJ, Wood, WH, Zhang, YQ, Becker, KG, Liu, ZQ, Gartenhaus, RB. Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. Cancer Res2008; 68: 7730–7735.CrossRefGoogle Scholar
28
28.Miller, JK, Shattuck, DL, Ingalla, EQ, Yen, LL, Borowsky, AD, Young, LJT, Cardiff, RD, Carraway, KL, Sweeney, C. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res2008; 68: 8286–8294.CrossRefGoogle ScholarPubMed